Malaysia deliberating over use of AstraZeneca COVID-19 vaccine after EU findings
08 April, 2021
Malaysia is deliberating whether to proceed with working with the AstraZeneca vaccine because of its national COVID-19 immunisation programme, following European Drugs Agency's (EMA) review.
Coordinating Minister intended for the Immunisation Programme Khairy Jamaluddin about Thursday (Apr 8) stated Malaysia has taken note of EMA’s announcement and that the vaccination committee will deliberate upon the matter.
“Safety is paramount,” he said in a content on Twitter.
The EMA on Wednesday said it found rare circumstances of bloodstream clots among some adult vaccine recipients, though it said the vaccine's advantages still outweighed the risks.
Malaysia features secured a complete of 12.8 million doses from AstraZeneca, half of which will come via the global COVAX facility.
Khairy said earlier that Malaysia even so has time to choose if it would utilize the AstraZeneca vaccine seeing as supplies is only going to arrive from the COVAX center in May.
Apart from AstraZeneca's vaccine, Malaysia features secured a total of 66.7 million vaccine doses from US drugmaker Pfizer-BioNTech, Russia's Gamaleya Institute, and China's Sinovac Biotech and CanSino Biologics.
In line with the minister, 80 % of the vaccines provided to Malaysia have already been dispensed to people young and old. Efforts have to be ramped up if the country is to accomplish its concentrate on of vaccinating 80 % of its population by December, he said.
Source: